(Q38575000)

4 September 2017

Nivolumab and pembrolizumab as immune-modulating monoclonal antibodies targeting the PD-1 receptor to treat melanoma (English)

1 reference

4 September 2017

1 reference

1 reference

4

1 reference

4 September 2017

Elnaz Faghfuri

1

0 references

author name string

Mohammad Ali Faramarzi

series ordinal

2

1 reference

PubMed ID

26313415

4 September 2017

Shekoufeh Nikfar

series ordinal

3

1 reference

4 September 2017

30 July 2015

1 reference

Expert Review of Anticancer Therapy

4 September 2017

1 reference

4 September 2017

15

1 reference

4 September 2017

9

1 reference

4 September 2017

981-993

1 reference

Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline

4 September 2017

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1074862

21 January 2018

Cancer statistics, 2014

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1074862

Melanoma: from melanocyte to genetic alterations and clinical options

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1074862

Metastatic behavior in melanoma: timing, pattern, survival, and influencing factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1074862

Efficacy and side effects of dacarbazine in comparison with temozolomide in the treatment of malignant melanoma: a meta-analysis consisting of 1314 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1074862

Latest approved therapies for metastatic melanoma: what comes next?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1074862

Vemurafenib for BRAF V600 mutated advanced melanoma: results of treatment beyond progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1074862

Anti-programmed death receptor 1 immunotherapy in melanoma: rationale, evidence and clinical potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1074862

CTLA-4 (CD152) inhibits T cell function by activating the ubiquitin ligase Itch.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1074862

Nivolumab in melanoma: latest evidence and clinical potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1074862

Clinical development of immunostimulatory monoclonal antibodies and opportunities for combination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1074862

Pembrolizumab: first global approval

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1074862

Role of the PD-1 pathway in the immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1074862

Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1074862

Nivolumab plus ipilimumab in advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1074862

Oncogenic BRAF(V600E) promotes stromal cell-mediated immunosuppression via induction of interleukin-1 in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1074862

Impact of NRAS mutations for patients with advanced melanoma treated with immune therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1074862

Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1074862

PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1074862

PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1074862

Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1074862

The evolution of checkpoint blockade as a cancer therapy: what's here, what's next?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1074862

Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1074862

Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1074862

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1074862

Nivolumab and ipilimumab versus ipilimumab in untreated melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1074862

Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1074862

Nivolumab in previously untreated melanoma without BRAF mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1074862

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1074862

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1074862

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1074862

A randomized controlled comparison of pembrolizumab and chemotherapy in patients with ipilimumab-refractory melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1074862

Pembrolizumab versus Ipilimumab in Advanced Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1074862

Emerging insights into resistance to BRAF inhibitors in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1074862

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1074862

Nivolumab: targeting PD-1 to bolster antitumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1074862

The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1074862

Nivolumab improved survival vs dacarbazine in patients with untreated advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1074862

A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1074862

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2015.1074862

10.1586/14737140.2015.1074862

21 January 2018

Identifiers

DOI

1 reference

4 September 2017

1 reference

PubMed ID

26313415